MX2022010465A - Compuestos de degradacion del receptor cinasa relacionado con trompomiosina y metodos de uso. - Google Patents
Compuestos de degradacion del receptor cinasa relacionado con trompomiosina y metodos de uso.Info
- Publication number
- MX2022010465A MX2022010465A MX2022010465A MX2022010465A MX2022010465A MX 2022010465 A MX2022010465 A MX 2022010465A MX 2022010465 A MX2022010465 A MX 2022010465A MX 2022010465 A MX2022010465 A MX 2022010465A MX 2022010465 A MX2022010465 A MX 2022010465A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- trk
- receptor kinase
- compounds
- tropomyosin receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020076748 | 2020-02-26 | ||
| PCT/CN2021/078240 WO2021170109A1 (en) | 2020-02-26 | 2021-02-26 | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010465A true MX2022010465A (es) | 2022-12-13 |
Family
ID=77490737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010465A MX2022010465A (es) | 2020-02-26 | 2021-02-26 | Compuestos de degradacion del receptor cinasa relacionado con trompomiosina y metodos de uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12410171B2 (enExample) |
| EP (1) | EP4110772A4 (enExample) |
| JP (1) | JP7692924B2 (enExample) |
| KR (1) | KR20230010070A (enExample) |
| CN (2) | CN120058711A (enExample) |
| AU (1) | AU2021225981A1 (enExample) |
| BR (1) | BR112022016901A2 (enExample) |
| CA (1) | CA3173262A1 (enExample) |
| IL (1) | IL295799A (enExample) |
| MX (1) | MX2022010465A (enExample) |
| WO (1) | WO2021170109A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| AU2019323446B2 (en) | 2018-08-22 | 2025-01-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| JP7692924B2 (ja) | 2020-02-26 | 2025-06-16 | クルゲン（シャンハイ），インク． | トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法 |
| WO2021185291A1 (zh) * | 2020-03-17 | 2021-09-23 | 南京明德新药研发有限公司 | 蛋白降解调节剂与其使用方法 |
| JP7814386B2 (ja) * | 2020-11-05 | 2026-02-16 | クロノス バイオ インコーポレイテッド | Ｃｄｋ９活性を調節するための化合物および方法 |
| WO2022161414A1 (zh) * | 2021-01-26 | 2022-08-04 | 成都茵创园医药科技有限公司 | 芳香化合物、含其的药物组合物及其应用 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023036175A1 (zh) * | 2021-09-08 | 2023-03-16 | 南京明德新药研发有限公司 | 戊二酰亚胺类化合物与其应用 |
| WO2023055952A1 (en) * | 2021-09-29 | 2023-04-06 | C4 Therapeutics, Inc. | Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds |
| KR20240110576A (ko) * | 2021-10-22 | 2024-07-15 | 글루탁스 테라퓨틱스 (상하이) 씨오., 엘티디. | Crbn e3 리가제 리간드 화합물, 리간드 화합물에 기초하여 개발된 단백질 분해제 및 이들의 응용 |
| EP4180428A1 (en) * | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
| CA3240524A1 (en) * | 2021-12-08 | 2023-06-15 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications |
| EP4455133A4 (en) * | 2021-12-24 | 2026-04-15 | Suzhou Kintor Pharmaceuticals Inc | MULTI-PROTEIN DEGRADING AGENT WITH AN IMIDE SKELETON |
| CN116217578B (zh) * | 2021-12-30 | 2026-02-24 | 清华大学 | 一类抑制mTOR同时降解GSPT1蛋白的双功能化合物 |
| TW202333670A (zh) * | 2022-01-04 | 2023-09-01 | 大陸商海思科醫藥集團股份有限公司 | 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用 |
| EP4480948A4 (en) * | 2022-02-14 | 2025-06-11 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Compound based on a quinazoline-substituted glutarimide skeleton and use thereof |
| KR20250004694A (ko) * | 2022-04-06 | 2025-01-08 | 클루젠 (상하이), 인크. | 암 치료를 위한 조성물 및 방법 |
| IL317668A (en) * | 2022-06-16 | 2025-02-01 | Prelude Therapeutics Inc | KAT6-targeted compounds with a ubiquitin ligase-binding residue |
| WO2024027792A1 (en) * | 2022-08-05 | 2024-02-08 | Shenzhen Newdel Biotech Co., Ltd. | Protein kinase degrading agent, medicament and use |
| CN117659020A (zh) * | 2022-09-07 | 2024-03-08 | 苏州朗睿生物医药有限公司 | 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途 |
| TW202444373A (zh) * | 2023-01-13 | 2024-11-16 | 大陸商深圳市新樾生物科技有限公司 | 化合物1在治療或預防特應性皮炎中的應用 |
| CN121843947A (zh) * | 2023-09-21 | 2026-04-10 | 成都茵创园医药科技有限公司 | Irak降解剂及其用途 |
| WO2025070690A1 (ja) | 2023-09-29 | 2025-04-03 | 第一三共株式会社 | ３－フェニルプロピルアミン誘導体 |
| WO2025155827A1 (en) * | 2024-01-18 | 2025-07-24 | St. Jude Children's Research Hospital, Inc. | Small-molecule modulators of lymphocyte-specific protein tyrosine kinase and casein kinase 1a |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
| CN119613482A (zh) * | 2024-12-09 | 2025-03-14 | 中国药科大学 | 具有端氨基结构的化合物及其制备方法、药物组合物和应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| ES2434946T3 (es) | 2005-08-31 | 2013-12-18 | Celgene Corporation | Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo |
| US8299057B2 (en) | 2007-07-20 | 2012-10-30 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| EP2300469B1 (en) | 2008-05-13 | 2015-06-24 | Novartis AG | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| EP2588129A4 (en) | 2010-06-30 | 2014-07-09 | Univ Brandeis | ON SMALL MOLECULES TARGETED PROTEIN REMOVAL |
| WO2012037155A2 (en) | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
| AU2011338615B2 (en) | 2010-12-07 | 2017-07-27 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| US20150119435A1 (en) | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| EP3097091A1 (en) | 2014-01-24 | 2016-11-30 | AbbVie Inc. | 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use |
| WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN119591582A (zh) | 2014-04-14 | 2025-03-11 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016096709A1 (en) * | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| GB201504314D0 (en) | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2016275051A1 (en) | 2015-06-10 | 2017-12-07 | Epizyme, Inc. | EZH2 inhibitors for treating lymphoma |
| CN105085620B (zh) | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
| CN108137507A (zh) | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | 基于mdm2的蛋白水解调节剂和相关的使用方法 |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| JP7037500B2 (ja) | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｍｄｍ２タンパク質分解剤 |
| AU2017246453A1 (en) | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| EP3455219A4 (en) * | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109562107A (zh) * | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109641874A (zh) * | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| KR101825065B1 (ko) | 2016-05-24 | 2018-02-05 | 한국화학연구원 | Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| GB201610156D0 (en) | 2016-06-10 | 2016-07-27 | Otsuka Pharma Co Ltd | Cliptac compositions |
| CA3025806C (en) | 2016-06-23 | 2023-04-04 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use |
| ES2857743T3 (es) | 2016-09-13 | 2021-09-29 | Univ Michigan Regents | 1,4-diazepinas fusionadas como degradadores de proteína BET |
| LT3660004T (lt) | 2016-10-11 | 2023-06-12 | Arvinas Operations, Inc. | Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai |
| EP3535265A4 (en) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| CN106543185B (zh) | 2016-11-10 | 2017-12-15 | 吉林大学 | 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| WO2018089736A1 (en) | 2016-11-10 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| AU2017382176A1 (en) | 2016-12-21 | 2019-05-30 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| EP3558994A4 (en) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| US11261179B2 (en) | 2017-04-14 | 2022-03-01 | University Of Dundee | Small molecules |
| CN108976278B (zh) | 2017-06-05 | 2021-04-06 | 海创药业股份有限公司 | 一种嵌合分子及其制备和应用 |
| US20180353501A1 (en) | 2017-06-09 | 2018-12-13 | Arvinas, Inc. | Modulators of proteolysis and associated methods of use |
| EP3725771B1 (en) * | 2017-12-13 | 2026-02-04 | Shanghaitech University | Alk protein degradation agent and anti-tumor application thereof |
| WO2020023549A1 (en) | 2018-07-24 | 2020-01-30 | January Therapeutics, Inc. | Nanoparticle compositions |
| AU2019323446B2 (en) | 2018-08-22 | 2025-01-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| JP7692924B2 (ja) | 2020-02-26 | 2025-06-16 | クルゲン（シャンハイ），インク． | トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法 |
| WO2023055952A1 (en) | 2021-09-29 | 2023-04-06 | C4 Therapeutics, Inc. | Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds |
-
2021
- 2021-02-26 JP JP2022551553A patent/JP7692924B2/ja active Active
- 2021-02-26 CA CA3173262A patent/CA3173262A1/en active Pending
- 2021-02-26 IL IL295799A patent/IL295799A/en unknown
- 2021-02-26 EP EP21760113.7A patent/EP4110772A4/en active Pending
- 2021-02-26 BR BR112022016901A patent/BR112022016901A2/pt unknown
- 2021-02-26 AU AU2021225981A patent/AU2021225981A1/en active Pending
- 2021-02-26 KR KR1020227033274A patent/KR20230010070A/ko active Pending
- 2021-02-26 MX MX2022010465A patent/MX2022010465A/es unknown
- 2021-02-26 CN CN202510191023.3A patent/CN120058711A/zh active Pending
- 2021-02-26 CN CN202180031506.7A patent/CN115697989B/zh active Active
- 2021-02-26 US US17/904,822 patent/US12410171B2/en active Active
- 2021-02-26 WO PCT/CN2021/078240 patent/WO2021170109A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL295799A (en) | 2022-10-01 |
| CN115697989A (zh) | 2023-02-03 |
| EP4110772A4 (en) | 2024-04-03 |
| US20230257380A1 (en) | 2023-08-17 |
| JP7692924B2 (ja) | 2025-06-16 |
| AU2021225981A1 (en) | 2022-09-29 |
| BR112022016901A2 (pt) | 2022-12-06 |
| CA3173262A1 (en) | 2021-09-02 |
| US12410171B2 (en) | 2025-09-09 |
| WO2021170109A1 (en) | 2021-09-02 |
| EP4110772A1 (en) | 2023-01-04 |
| KR20230010070A (ko) | 2023-01-17 |
| CN115697989B (zh) | 2025-03-18 |
| JP2023514872A (ja) | 2023-04-11 |
| CN120058711A (zh) | 2025-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021001957A (es) | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). | |
| BR112022016901A2 (pt) | Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso | |
| CY1126152T1 (el) | Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων | |
| JOP20210337A1 (ar) | مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1 | |
| MX2023008330A (es) | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. | |
| JOP20200278B1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| PH12022551462A1 (en) | Ilt3-binding agents and methods of use thereof | |
| MX2024000611A (es) | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso. | |
| BRPI0813625A2 (pt) | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 | |
| CY1118846T1 (el) | Τριαζολοπυριδαζινες ως ρυθμιστες της κινασης τυροσινης | |
| EA200800546A1 (ru) | Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk) | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| MX2010004244A (es) | Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk). | |
| NO20084435L (no) | C-MET proteinkinaseinhibitorer | |
| PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| CY1113257T1 (el) | Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων | |
| CY1113642T1 (el) | Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl | |
| DE602006012725D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| MX2024014830A (es) | Compuestos de degradacion de wee1 y usos de los mismos | |
| MX2022005976A (es) | Compuestos antagonistas de receptores de adenosina. | |
| MX2021005740A (es) | Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo. | |
| MX2025006740A (es) | Composiciones farmacéuticas que contienen una de piperidinil-metil-purina amina y su uso en el tratamiento de enfermedades y afecciones | |
| BR112023018816A2 (pt) | Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença |